Value
7.5/10data confidence 33%| Component | Sub-score |
|---|---|
| Analyst target | 7.5 |
- ▸Attractively valued
NAMS · Why this verdict
Why NewAmsterdam Pharma Company (NAMS) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.3/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
NewAmsterdam's entire value proposition rests on obicetrapib, a single pipeline asset — meaning that a clinical setback, regulatory delay, or competitor approval would substantially impair or eliminate the investment thesis with no diversification buffer. Bear case | Obicetrapib advances without a clinical hold or material safety signal for the next 12 months, preserving the optionality embedded in the analyst target. | →Stable |
| CounterSingle-asset biotechs that reach late-stage development often command premium valuations because focus allows faster execution and cleaner regulatory narratives than diversified pipelines. | ||
The company burns cash at 260% of revenue — meaning it spends far more than it earns from operations — and has a Rule of 40 score of -258, flagging that the current cash runway is a critical risk if capital markets access tightens or trial timelines extend. Quality breakdown | Cash burn rate declines below 200% of revenue within 4 quarters as clinical expenses normalize toward a late-stage trial completion. | →Stable |
| CounterPre-commercial biotechs routinely burn cash at high multiples of revenue during clinical development; this is priced into the category and the relevant question is runway length, not burn ratio. | ||
Analysts see approximately 64% upside to their consensus price target of $43.59, among the largest upside spreads in the healthcare coverage universe, reflecting conviction that obicetrapib's market opportunity is not priced into the current $30.60 stock. Sentiment breakdown | The stock price rises above $40 (increases more than 30% from current levels) within 12 months following a positive clinical or regulatory milestone. | →Stable |
| CounterAnalyst targets for pre-profitability biotechs are often model-dependent on trial success probability assumptions; a miss or partial data readout can cause targets to collapse by 50% or more overnight. | ||
The stock is in a death-cross setup with all moving averages declining, RSI at 25 (near oversold capitulation), and a bearish MACD — a combination that historically indicates sustained selling pressure without a near-term reversal catalyst. V9 | The RSI rises above 40 and the 50-day moving average stops declining within 60 days following a positive clinical announcement or earnings beat. | →Stable |
| CounterBiotech stocks in confirmed downtrends can reverse abruptly and violently on a single positive data readout; technical patterns carry lower predictive weight in event-driven names than in other sectors. | ||
NewAmsterdam's entire value proposition rests on obicetrapib, a single pipeline asset — meaning that a clinical setback, regulatory delay, or competitor approval would substantially impair or eliminate the investment thesis with no diversification buffer.
→StableBear case
- Expectation
- Obicetrapib advances without a clinical hold or material safety signal for the next 12 months, preserving the optionality embedded in the analyst target.
CounterSingle-asset biotechs that reach late-stage development often command premium valuations because focus allows faster execution and cleaner regulatory narratives than diversified pipelines.
The company burns cash at 260% of revenue — meaning it spends far more than it earns from operations — and has a Rule of 40 score of -258, flagging that the current cash runway is a critical risk if capital markets access tightens or trial timelines extend.
→StableQuality breakdown
- Expectation
- Cash burn rate declines below 200% of revenue within 4 quarters as clinical expenses normalize toward a late-stage trial completion.
CounterPre-commercial biotechs routinely burn cash at high multiples of revenue during clinical development; this is priced into the category and the relevant question is runway length, not burn ratio.
Analysts see approximately 64% upside to their consensus price target of $43.59, among the largest upside spreads in the healthcare coverage universe, reflecting conviction that obicetrapib's market opportunity is not priced into the current $30.60 stock.
→StableSentiment breakdown
- Expectation
- The stock price rises above $40 (increases more than 30% from current levels) within 12 months following a positive clinical or regulatory milestone.
CounterAnalyst targets for pre-profitability biotechs are often model-dependent on trial success probability assumptions; a miss or partial data readout can cause targets to collapse by 50% or more overnight.
The stock is in a death-cross setup with all moving averages declining, RSI at 25 (near oversold capitulation), and a bearish MACD — a combination that historically indicates sustained selling pressure without a near-term reversal catalyst.
→StableV9
- Expectation
- The RSI rises above 40 and the 50-day moving average stops declining within 60 days following a positive clinical announcement or earnings beat.
CounterBiotech stocks in confirmed downtrends can reverse abruptly and violently on a single positive data readout; technical patterns carry lower predictive weight in event-driven names than in other sectors.
TrendMatrix Research · core thesis
Engine thesis — one sentence
NewAmsterdam Pharma is a pre-profitability biotech with a single pipeline asset in obicetrapib and analysts seeing 64% upside, but the stock is in a technical falling-knife pattern with RSI at 25, 2 of 4 recent earnings misses, and cash burning at 260% of revenue — making the risk profile extremely asymmetric in both directions.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
3.4/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 10.0 |
| Net margin | 0.0 |
| Current ratio | 5.0 |
| FCF quality | 0.0 |
| Moat | 6.1 |
| Rule of 40 | 3.0 |
| Piotroski F | 6.7 |
- ▸Cash-burning: FCF -260% of revenue
- ▸Rule of 40: -258 (fail)
Growth
3.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Rev growth | 3.0 |
Momentum
7.3/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.2 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 9.0 |
| Volume | 3.4 |
- ▸Overbought (RSI 77)
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
8.5/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 7.8 |
| Analyst rating | 8.6 |
| Price target | 9.3 |
- ▸LLM news sentiment: +0.55 (n=1)
- ▸Analyst upside: 43%
Insider
3.9/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 4.5 |
| insider conviction | 2.0 |
| holder change | 5.1 |
- ▸Modest insider selling — $3,528,009 (0.087% of mkt cap)
Peer rank
6.2/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 6.0 |
| growth rank | 3.9 |
- ▸Conservative debt levels
Technical
3.0/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.5 |
| support resistance | 2.1 |
| 52w position | 6.5 |
Risk (lower is worse)
5.7/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 5.4 |
| days to cover | 3.2 |
| volatility | 1.4 |
| put call | 10.0 |
| implied vol | 0.0 |
| beta | 10.0 |
| debt equity | 10.0 |
- ▸High IV: 95%
- ▸Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
3.8/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 3.3 |
| earnings timing | 5.0 |
| surprise avg | 0.9 |
| news activity | 5.0 |
- ▸Earnings concerns: 2B/2M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (7)
- MOMENTUM:7.3>=5.5
- ASYMMETRY:1.6>=1.5
- INSIDER:OK
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:33d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (0)
none
Warning (1)
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
1.62
Upside
+24.3%
Downside
15.0%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Sentiment at 8.5 could not lift the engine output above the verdict floor.
The strongest dimensions are Sentiment at 8.5, Value at 7.5, and Momentum at 7.3; the weakest are Technical at 3.0, Growth at 3.0, and Quality at 3.4. The V9 engine cleared all gates with 1 warning, producing an asymmetric reward-to-risk of 1.62 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Single Asset Obicetrapib Concentration
Trip ifAny clinical hold, partial clinical failure, or safety signal emerges for obicetrapib, causing analyst price target to decline below $25 (more than 42% below current $43.59 target).
- P2High Analyst Upside Target Conviction
Trip ifAnalyst consensus price target declines below $30 (falls more than 31% from the current $43.59 target).
- P3Cash Burn And Solvency Risk
Trip ifCash burn exceeds 300% of revenue for 2 consecutive quarters or management discloses that runway is less than 12 months.
- P4Falling Knife Technical Pattern
Trip ifRSI falls below 15 or the stock price drops below $25 (falls more than 18% below current $30.60) without a corresponding positive catalyst.